Value assessment of new interventions for Alzheimer's disease dementia in Japan based on literature review and group interview
INTRODUCTION: With an increase in the number of patients with Alzheimer's disease dementia (ADD), new health technologies have been developed to address the problem. We propose an optimal way to assess the disease burden and treatment value of ADD in Japan by considering the characteristics of the disease.
AREAS COVERED: We performed literature searches and a group interview with professional care workers to obtain information on the items that would facilitate the assessment of the value of ADD intervention. We determined the items as patient quality of life (QOL), medical costs, caregiver QOL, public long-term care costs, and informal care costs.
EXPERT OPINION: There are several limitations to how QOL is measured, particularly for patients with ADD. Public long-term care costs represent a substantial proportion of total costs and should be included in the assessment and decision-making of ADD, even from the payer's perspective. Following that, a process is required to take informal care costs into account in decision-making, regardless of whether they are included or not in a base-case analysis. The importance of other elements of care burden that cannot be quantitatively measured should also be recognized and reflected in decision-making.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Expert review of pharmacoeconomics & outcomes research - 22(2022), 8 vom: 30. Dez., Seite 1163-1170 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Igarashi, Ataru [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer’s disease dementia |
|---|
| Anmerkungen: |
Date Completed 10.11.2022 Date Revised 10.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14737167.2022.2118113 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34557169X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34557169X | ||
| 003 | DE-627 | ||
| 005 | 20231226025348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737167.2022.2118113 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM34557169X | ||
| 035 | |a (NLM)36039772 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Igarashi, Ataru |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Value assessment of new interventions for Alzheimer's disease dementia in Japan based on literature review and group interview |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.11.2022 | ||
| 500 | |a Date Revised 10.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: With an increase in the number of patients with Alzheimer's disease dementia (ADD), new health technologies have been developed to address the problem. We propose an optimal way to assess the disease burden and treatment value of ADD in Japan by considering the characteristics of the disease | ||
| 520 | |a AREAS COVERED: We performed literature searches and a group interview with professional care workers to obtain information on the items that would facilitate the assessment of the value of ADD intervention. We determined the items as patient quality of life (QOL), medical costs, caregiver QOL, public long-term care costs, and informal care costs | ||
| 520 | |a EXPERT OPINION: There are several limitations to how QOL is measured, particularly for patients with ADD. Public long-term care costs represent a substantial proportion of total costs and should be included in the assessment and decision-making of ADD, even from the payer's perspective. Following that, a process is required to take informal care costs into account in decision-making, regardless of whether they are included or not in a base-case analysis. The importance of other elements of care burden that cannot be quantitatively measured should also be recognized and reflected in decision-making | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alzheimer’s disease dementia | |
| 650 | 4 | |a caregiver burden | |
| 650 | 4 | |a group interview | |
| 650 | 4 | |a health technology assessment | |
| 650 | 4 | |a informal care | |
| 650 | 4 | |a literature review | |
| 650 | 4 | |a patient care | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a value assessment | |
| 700 | 1 | |a Ikeda, Shunya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of pharmacoeconomics & outcomes research |d 2001 |g 22(2022), 8 vom: 30. Dez., Seite 1163-1170 |w (DE-627)NLM187860815 |x 1744-8379 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:8 |g day:30 |g month:12 |g pages:1163-1170 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14737167.2022.2118113 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 8 |b 30 |c 12 |h 1163-1170 | ||